Open-Label Surufatinib in European Patients With NET

Active:	No
Cancer Type:	Neuroendocrine Tumor	NCT ID:	NCT04579679
Trial Phases:	Phase II	Protocol IDs:	2020-012-00EU1 (primary) NCI-2022-06079
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Hutchmed
NCI Full Details:	http://clinicaltrials.gov/show/NCT04579679

Summary

This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to
intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).

Objectives

This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low- to
intermediate-grade (Grade 1 or Grade 2), well-differentiated NETs.

The study will enroll 4 cohorts of varying NETs, as follows:

- Cohort A - NET of lung origin

- Cohort B - NET of small bowel origin

- Cohort C - NET of non-small bowel, non-pancreas, and non-lung origin

- Cohort D - NET of any origin (DDI substudy)

All patients will be treated with oral surufatinib 300 mg QD in treatment cycles of 28 days
starting on Cycle 1 Day 1.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.